FOXP3 and in situ carcinoma: But importantly, immune-suppressor, CD4+CD25+Foxp3+ Treg cells, which showed a gradual increase with progression of dysplasia to carcinoma in situ in 4NQO cohort, is significantly reduced after NLGP treatment.